Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;14(2):186-188.
doi: 10.1111/jdi.13951. Epub 2022 Dec 1.

Current understanding of imeglimin action on pancreatic β-cells: Involvement of mitochondria and endoplasmic reticulum homeostasis

Muhammad Fauzi  1 , Takaaki Murakami  1 , Daisuke Yabe  2 , Nobuya Inagaki  1   3
Affiliations

Current understanding of imeglimin action on pancreatic β-cells: Involvement of mitochondria and endoplasmic reticulum homeostasis

Muhammad Fauzi et al. J Diabetes Investig. 2023 Feb.

Abstract

Recent preclinical studies have provided insight on imeglimin's action on pancreatic β-cells and the mechanisms underlying its clinical benefits. Imeglimin may enhance glucose-induced insulin secretion (GIIS) and inhibit apoptosis of pancreatic ß-cells leading to preserved β-cell mass by maintaining or restoring the functional and structural integrity of the mitochondria and the endoplasmic reticulum homeostasis in pancreatic β-cells.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Multifaceted actions of imeglimin on pancreatic β‐cells. Imeglimin improves the mitochondrial function and structural integrity and restores homeostasis of the endoplasmic reticulum (ER). These actions might lead to preservation of β‐cell mass as well as enhancement of glucose‐induced insulin secretion (GIIS).
See this image and copyright information in PMC

References

    1. Fouqueray P, Leverve X, Fontaine E, et al. Imeglimin – a new oral anti‐diabetic that targets the three key defects of type 2 diabetes. J Diabetes Metab 2011; 2: 126.
    1. Hallakou‐Bozec S, Vial G, Kergoat MF, et al. Mechanism of action of imeglimin: a novel therapeutic agent for type 2 diabetes. Diabetes Obes Metab 2021; 23: 664–673. - PMC - PubMed
    1. Sanada J, Obata A, Fushimi Y, et al. Imeglimin exerts favorable effects on pancreatic β‐cells by improving morphology in mitochondria and increasing the number of insulin granules. Sci Rep 2022; 12: 13220. - PMC - PubMed
    1. Fauzi M, Murakami T, Fujimoto H, et al. Preservation effect of imeglimin on pancreatic β‐cell mass: noninvasive evaluation using 111In‐exendin‐4 SPECT/CT imaging and the perspective of mitochondrial involvements. Front Endocrinol 2022; 13: 1010825. - PMC - PubMed
    1. Li J, Inoue R, Togashi Y, et al. Imeglimin ameliorates β‐cell apoptosis by modulating the endoplasmic reticulum homeostasis pathway. Diabetes 2022; 71: 424–439. - PubMed